Save information for later
Sign Up

Learn About Tuberous Sclerosis Complex

What is the definition of Tuberous Sclerosis Complex?

Tuberous sclerosis complex is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. These tumors can occur in the brain, kidneys, heart, skin, and other organs, in some cases leading to significant health problems. Tuberous sclerosis complex also causes developmental problems, and the signs and symptoms of the condition vary from person to person.

What are the causes of Tuberous Sclerosis Complex?

Variants (also known as mutations) in the TSC1 or TSC2 gene can cause tuberous sclerosis complex. The TSC1 and TSC2 genes provide instructions for making the proteins hamartin and tuberin, respectively. Within cells, these two proteins work together to help regulate cell growth and division (proliferation) and cell size. The proteins act as tumor suppressors, which normally prevent cells from growing and dividing too fast or in an uncontrolled way.

How prevalent is Tuberous Sclerosis Complex?

Tuberous sclerosis complex affects 1 in 6,000 to 10,000 people.

Is Tuberous Sclerosis Complex an inherited disorder?

Tuberous sclerosis complex has an autosomal dominant pattern of inheritance, which means one copy of the altered gene in each cell is sufficient to increase the risk of developing tumors and other problems with development. In about one-third of cases, an affected person inherits an altered TSC1 or TSC2 gene from a parent who has the disorder. The remaining two-thirds of people with tuberous sclerosis complex are born with new variants in the TSC1 or TSC2 gene. These cases, which are described as sporadic, occur in people with no history of tuberous sclerosis complex in their family. TSC1 gene variants appear to be more common in familial cases of tuberous sclerosis complex, while variants in the TSC2 gene occur more frequently in sporadic cases.

Who are the top Tuberous Sclerosis Complex Local Doctors?
Elite in Tuberous Sclerosis Complex
Elite in Tuberous Sclerosis Complex

C H Neurology Foundation Inc

300 Longwood Ave, 
Boston, MA 
Languages Spoken:
English

Jurriaan Peters is a Pediatrics provider in Boston, Massachusetts. Dr. Peters is rated as an Elite provider by MediFind in the treatment of Tuberous Sclerosis Complex. His top areas of expertise are Tuberous Sclerosis Complex, Tuberous Sclerosis, Cortical Dysplasia, Seizures, and Prostatectomy.

Elite in Tuberous Sclerosis Complex
Elite in Tuberous Sclerosis Complex

Office

730 Welch Rd Ste 206, 
Palo Alto, CA 
Languages Spoken:
English

Brenda Porter is a Neurologist in Palo Alto, California. Dr. Porter is rated as an Elite provider by MediFind in the treatment of Tuberous Sclerosis Complex. Her top areas of expertise are Seizures, Tuberous Sclerosis, Tuberous Sclerosis Complex, Epilepsy, and Deep Brain Stimulation.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Tuberous Sclerosis Complex
Pediatrics
Elite in Tuberous Sclerosis Complex
Pediatrics

Office

9560 Children Dr Ste A, 
Mason, OH 
Languages Spoken:
English
Offers Telehealth

David Neal is a Pediatrics provider in Mason, Ohio. Dr. Neal is rated as an Elite provider by MediFind in the treatment of Tuberous Sclerosis Complex. His top areas of expertise are Tuberous Sclerosis, Tuberous Sclerosis Complex, Cortical Dysplasia, and Seizures.

What are the latest Tuberous Sclerosis Complex Clinical Trials?
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)

Summary: 1\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures

Summary: Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Who are the sources who wrote this article ?

Published Date: January 04, 2022
Published By: National Institutes of Health